Skip to main content
Numinus logo
  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Why Invest
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Financial Overview
      • Sedar Filings
    • Governance
      • Executive Management
      • Board of Directors
      • Governance Documents
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Why Invest
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Financial Overview
      • Sedar Filings
    • Governance
      • Executive Management
      • Board of Directors
      • Governance Documents
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management

  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Why Invest
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Financial Overview
      • Sedar Filings
    • Governance
      • Executive Management
      • Board of Directors
      • Governance Documents
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management Carousel

Payton Nyquvest (He/Him), Founder & CEO

Payton is the Founder, Chair & Chief Executive Officer of Numinus, and is passionate about empowering people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. He has a deep understanding of the psychedelic industry from its infancy, driven by life-saving personal experiences with multiple therapy modalities. Additionally, Payton has deep business leadership experience, particularly in the finance sector, and is a recognized innovator and visionary in mental health care. He is responsible for raising more than $70 million for Numinus, and is quoted widely in media such as CTV, Forbes and the New York Times. In addition, he brings more than 15 years working in finance, investment and retail banking with some of Canada’s leading independent investment firms, including Jordan Capital Markets, Canaccord Financial and Mackie Research Capital. In these and other roles, he has raised more than $100 million for a variety of small cap companies.

Michael Tan (He/Him), President & Chief Operating Officer

Former/first Executive Director, BCLDB Cannabis Division. Successfully launched recreational cannabis operations in BC. Twenty years’ operations management, strategic planning, and execution with national and multinational corporations including Hudson’s Bay, Saks Fifth Avenue, and UPS. Seasoned, high-impact operations, product development, and marketing executive with a track record of driving performance excellence and profitable revenue growth.

John Fong (He/Him), Chief Financial Officer

Experienced financial operator growing technology companies for the past five years, most recently as Managing Director of Invoke Digital. Prior to that, spent 15 years building international financial operations with companies listed on the TSX, NYSE, London AIM, and Lima Stock Exchange, the highlight of which was being on the founding team of Rio Alto Mining, a gold company that in three years went from exploration stage to generating net income of $100 million and operating cash flow of $98 million in its first year of commercial production.

Portrait

Dr. Reid Robison, MD, MBA (He/Him), Chief Clinical Officer

Psychiatry leader and co-founder of Cedar Psychiatry. Recognized for leading research and treatment of eating disorders (EDs), early adoption of ketamine in psychiatry, and social entrepreneurship. Previously coordinating investigator in a MAPS-sponsored study on MDMA for EDs and lead of a Janssen study on ketamine for treatment-resistant depression. Dr. Robison was previously Chief Medical Officer at Novamind.
Portrait

Dr. Paul Thielking, MD (He/Him), Chief Science Officer

Certified psychiatry, hospice/palliative medicine, and integrative medicine leader and trained in psychedelic therapy (CIIS). Extensive experience developing interventions for people with serious illness and substance use disorders, including psilocybin for depression in cancer patients, ketamine for opioid use, and tobacco treatment. Dr. Thielking was previously Chief Scientific Officer at Novamind.

Quick Links

  • Investor FAQs
  • Information Request Form
  • Sign up for Investor Email Alerts

IR Contact

+1 833-686-4687
invest@numinus.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Numinus, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Numinus, Inc. to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*



Unsubscribe

Email Alert Sign Up Confirmation

  • Privacy Policy
  • Forward Looking Statements
  • Terms of Service
© Numinus Wellness Inc. - All rights reserved